Ajanta Pharma · NSE: AJANTPHARM · BSE: 532331
Q1 FY20 results · Apr–Jun 2019
Ajanta Pharma reported revenue from operations of ₹611.94 crore (up 19.8% from Q1 FY19) and net profit of ₹114.63 crore (up 8.4% from Q1 FY19) for Q1 FY20 (Apr–Jun 2019), on a consolidated basis.
| Item | Q1 FY20 | Q1 FY19 | YoY | Q4 FY19 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 611.94 | 510.99 | +19.8% | 515.16 | +18.8% |
| Other income | 7.64 | 8.13 | −6.0% | 1.63 | +368.7% |
| Total income | 619.58 | 519.12 | +19.4% | 516.79 | +19.9% |
| Profit before tax | 151.45 | 148.28 | +2.1% | 109.19 | +38.7% |
| Net profit for the period | 114.63 | 105.79 | +8.4% | 88.89 | +29.0% |
| Attributable to shareholders of the company | 113.33 | 105.79 | +7.1% | 88.83 | +27.6% |
| EPS, basic (₹) | 13.14 | 12.02 | +9.3% | 10.10 | +30.1% |
| Net margin (%) | 18.7 | 20.7 | 17.3 |
| Item | Q1 FY20 | Q1 FY19 | YoY | Q4 FY19 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 545.74 | 441.95 | +23.5% | 413.53 | +32.0% |
| Other income | 39.62 | 69.06 | −42.6% | 3.19 | 12x |
| Total income | 585.36 | 511.01 | +14.5% | 416.72 | +40.5% |
| Profit before tax | 156.45 | 193.36 | −19.1% | 52.01 | +200.8% |
| Net profit for the period | 123.60 | 150.82 | −18.0% | 41.37 | +198.8% |
| EPS, basic (₹) | 14.17 | 17.14 | −17.3% | 4.70 | +201.4% |
| Net margin (%) | 22.6 | 34.1 | 10.0 |
Consolidated
- Filed with BSE
- 01 Aug 2019, 11:43 IST
- Board meeting
- 31 Jul 2019
- Period
- 01 Apr 2019 to 30 Jun 2019
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 01 Aug 2019, 11:43 IST
- Board meeting
- 31 Jul 2019
- Period
- 01 Apr 2019 to 30 Jun 2019
- Review status
- Unaudited
- Source
- XBRL filing on BSE